



Elizabeth O'Day, CEO

Olaris develops a metabolomics platform and machine learning algorithms to help identify the most effective therapies for disease. Through the course of the program, Liz was able to make key hires including Sr. Director of Data Science and COO, and has completed an additional financing round. In addition, the company has filed preliminary patents on the assay they are developing. Beyond this, Liz was selected as the Co-Chair of the Global Future Council on Biotechnology at the World Economic Forum, and was invited to participate in the Biden Cancer Summit.




Vera Hoffman, CEO

Hoffman and her company are working to develop a manganese based contrast agent that improves upon the safety of gadolinium-based agents without compromising efficacy. Reveal Pharmaceuticals has been able to make additional hires through the money they received as part of MassNextGen. Beyond this funding, the company was awarded a supplemental NIH grant. The field itself has also progressed during MassNextGen and multiple papers and articles supporting the basis for Reveal's technology, that Gadolinium based imaging agents are retained in the cerebrospinal fluid and the brain.



Yue Shao, President

In order for therapeutic hypothermia to be effective, it must be administered quickly and have large cooling capacity, Buy Time Medical improves upon this through a medical ice slurry and catheter solution. During the course of the program, Yue was able to complete the NIH iCorps program and gained connections needed for interviews from the individuals they met through MassNextGen. In addition, the company has started speaking with physicians to help them determine the best path forward for their innovative technology.



Akshaya Shanmugam, CEO

Using machine learning and big data analytics, Shanmugam co-founded Lumme to develop a software platform that can disrupt the treatment of addiction. Their first application is in the field of smoking cessation, via smartphone application and wearable sensors. Over the course of the program, Lumme was featured on NECN business and participated in HubWeek demo day. Beyond this, the company is engaged in many conversations with corporations to offer the technology to their employees. In addition, Akshaya was named one of MedTech Boston's 40 under 40 healthcare innovators and is presenting the technology to congress.



Laura Indolfi, President and CEO

PanTher is developing a drug embedded polymeric matrix that is capable of delivering tailored chemotherapy release from weeks to several months. Over the course of this year, Laura has presented at the BIO investors meeting, was named a JLABs Company through Johnson and Johnson, and finally was awarded a LabCentral Golden Ticket.





Azadeh Khanicheh, President

Khanicheh brings 15 years of experience in the medical device innovation and research space. After receiving her PhD in Mechanical and Biomedical Engineering from Northeastern she worked throughout Massachusetts, including 15 issued and pending patents. EnVision Endoscopy is working on a suturing adjunct that can be used with any endoscope. By decreasing the number of steps and procedure time, the cost is decreased and this allows for access to a greater number of gastroenterologists and surgeons.



Cohort Two



Carmela Mascio, President and CSO

As the CSO, Mascio brings experience in infection control and leading new strategic initiatives, most recently at Cubist. She has worked in the microbiology and antibacterial spaces for over 15 years. Mascio has been recognized for her work with STEM education. LivOnyx expands on this experience and is developing a novel hand disinfection system that provides quicker, easier, and more complete disinfection and can increase health care workers compliance with hand sanitation guidelines. As a result, the prevalence of healthcare associated infections can be decreased, while improving hand health of practitioners.



Amy Ripka, CEO and President

Ripka brings 20 years of drug discovery experience and expertise to her role at Lucy Therapeutics. She has over 30 issued chemical patents and has worked in drug discovery from screening to IND. Ripka has also led international research conferences and served as scientific advisor to multiple biotechs. She is applying this experience to LucyTx's goal of generating a new platform for the discovery of neurological therapies, first focusing on Rett Syndrome. LucyTx's targets focus on the mitochondria, which are disproportionately affected in these diseases.



Minmin Yen, CEO

Yen is a recent PhD graduate from Tufts University. During her tenure there, she worked on developing a bacteriophage product to combat household transmission of cholera. PhagePro was founded to not only continue this work but also develop phage products for emerging markets. Their initial target is cholera and by offering an oral product that offers immediate protection, families of patients infected with cholera will be able to take care of their loved ones without fear while also curbing outbreaks in the community. Yen has been recognized as a MIT Technology Review 35 Innovators Under 35 as a Humanitarian Innovator and has participated in MassConnect.



Suzanne Mitchell, CEO

Mitchell is a physician researcher that designs and studies the impact of digital health for improved health service delivery for chronic and serious illness. She has 20 years of clinical and research experience on implementation science. Mitchell leverages her experience through See Yourself Health to develop a digital health platform to empower and prepare people to reverse the course of diabetes in their lives. The technology uses virtual reality and innovative programming to generate a comprehensive toolkit for chronic disease and population health management.



MASS NEXT GEN